Tesaro’s Niraparib Takes PARP Inhibitor Lead In Ovarian Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Tesaro Inc. announced the launch of a Phase III trial for its PARP inhibitor niraparib in ovarian cancer, while registrational data from three global Phase III studies for anti-emetic rolapitant are due by the end of 2013.
You may also be interested in...
Merck Expands Keytruda Trial Collaboration With Amgen, Unveils Others
Merck’s sBLA for Keytruda in lung cancer has been accepted by FDA and granted an Oct. 2 action date, the firm announced. The company also revealed several new research collaborations to study Keytruda in more combination trials at ASCO.
Deals Of The Week Looks At 2014 Takeout Targets
The hot field of immuno-oncology once again dominated the deal landscape with tie-ups between Bristol and Five Prime, Tesaro and AntaptysBio, and Medimmune and MD Anderson. Kythera and Bayer parted ways while Sanofi Pasteur teamed up with SK Chemicals.
Tesaro On Track For Mid-Year NDA Filing Of Oral CINV Candidate Rolapitant
While awaiting data from the third and final Phase III trial of the oral cancer supportive care candidate, Tesaro also will advance an I.V. formulation of rolapitant. Meanwhile, PARP inhibitor niraparib is in two Phase III trials in oncology indications, with a plan to seek other tumor types the compound might treat.